Big Pharma's Best Friends
Scott Gottlieb
Scott Gottlieb was commissioner of the Food and Drug Administration (FDA) at HHS from May 2017 until he resigned in April 2019.
Prior to his stint as FDA commissioner, Gottlieb received income from various pharmaceutical companies. These include:
- Served as a member of the R&D Portfolio Investment Board of GlaxoSmithKline plc, receiving $87,153 in consulting fees.
- Served as an independent member of the Boards of Directors for Daiichi Sankyo U.S. (receiving $52,207), and Tolero Pharmaceuticals (receiving $37,500).
- Received at least $97,750 in speaking honorariums from: Merck & Co., Milkart Pharma, Pharmacy Benefit Managers Institute, Mallinckrodt Pharmaceuticals, CVS Health, Johnson & Johnson, Biogen, Inc., Generic Pharmaceutical Association, and InVentiv Health, Inc.
- Received $193,111 after selling his Tolero Pharmaceuticals stock options and still held nearly 98,000 shares (for which he did not report the value).
In June 2019, Pfizer named Gottlieb to its board of directors.
[Sources: FDA.Gov; Scott Gottlieb Financial Disclosure; Pfizer]